These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29460668)

  • 21. Standards for opioid treatment in the criminal justice system: implications for nurses.
    Chavez RS
    J Addict Nurs; 2012 Feb; 23(1):40-6. PubMed ID: 22468659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naltrexone pharmacotherapy for opioid dependent federal probationers.
    Cornish JW; Metzger D; Woody GE; Wilson D; McLellan AT; Vandergrift B; O'Brien CP
    J Subst Abuse Treat; 1997; 14(6):529-34. PubMed ID: 9437624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis.
    Suzuki J; Robinson D; Mosquera M; Solomon DA; Montgomery MW; Price CD; Johnson JA; Martin B; Liebschutz JW; Schnipper JL; Weiss RD
    Am J Addict; 2020 Mar; 29(2):155-159. PubMed ID: 31930608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study.
    Rabinowitz J; Cohen H; Tarrasch R; Kotler M
    Drug Alcohol Depend; 1997 Aug; 47(2):77-86. PubMed ID: 9298329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Research on naltrexone in the criminal justice system.
    Patapis NS; Nordstrom BR
    J Subst Abuse Treat; 2006 Sep; 31(2):113-5. PubMed ID: 16919735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia.
    Larney S; Zador D; Sindicich N; Dolan K
    Drug Alcohol Rev; 2017 May; 36(3):305-310. PubMed ID: 27325289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
    Coviello DM; Cornish JW; Lynch KG; Boney TY; Clark CA; Lee JD; Friedmann PD; Nunes EV; Kinlock TW; Gordon MS; Schwartz RP; Nuwayser ES; O'Brien CP
    Subst Abus; 2012; 33(1):48-59. PubMed ID: 22263713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prompted to treatment by the criminal justice system: Relationships with treatment retention and outcome among cocaine users.
    Kiluk BD; Serafini K; Malin-Mayor B; Babuscio TA; Nich C; Carroll KM
    Am J Addict; 2015 Apr; 24(3):225-232. PubMed ID: 25809378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015.
    Mantha S; Mauro PM; Mauro CM; Martins SS
    Drug Alcohol Depend; 2020 Jan; 206():107654. PubMed ID: 31735533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
    Klein AA; Seppala MD
    J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioid Agonist Treatment Recipients within Criminal Justice-Involved Populations.
    Guastaferro WP; Koetzle D; Lutgen-Nieves L; Teasdale B
    Subst Use Misuse; 2022; 57(5):698-707. PubMed ID: 35172673
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacological interventions for drug-using offenders.
    Perry AE; Neilson M; Martyn-St James M; Glanville JM; McCool R; Duffy S; Godfrey C; Hewitt C
    Cochrane Database Syst Rev; 2013 Dec; (12):CD010862. PubMed ID: 24353217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
    Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
    Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
    Herscher M; Fine M; Navalurkar R; Hirt L; Wang L
    Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing an index to measure the voluntariness of consent to research.
    Dugosh KL; Festinger DS; Marlowe DB; Clements NT
    J Empir Res Hum Res Ethics; 2014 Oct; 9(4):60-70. PubMed ID: 25747297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
    Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
    Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.